gms | German Medical Science

14th Triennial Congress of the International Federation of Societies for Surgery of the Hand (IFSSH), 11th Triennial Congress of the International Federation of Societies for Hand Therapy (IFSHT)

17.06. - 21.06.2019, Berlin

The introduction of human Mesenchymal Stem Cells to clinically available nerve substitutes

Meeting Abstract

  • presenting/speaker Femke Mathot - Mayo Clinic, Rochester, United States
  • Nadia Rbia - Mayo Clinic, Rochester, United States
  • Allen Bishop - Mayo Clinic, Rochester, United States
  • Andre Van Wijnen - Mayo Clinic, Rochester, United States
  • Alexander Shin - Mayo Clinic, Rochester, United States

International Federation of Societies for Surgery of the Hand. International Federation of Societies for Hand Therapy. 14th Triennial Congress of the International Federation of Societies for Surgery of the Hand (IFSSH), 11th Triennial Congress of the International Federation of Societies for Hand Therapy (IFSHT), 11th Triennial Congress of the International Federation of Societies for Hand Therapy (IFSHT). Berlin, 17.-21.06.2019. Düsseldorf: German Medical Science GMS Publishing House; 2020. DocIFSSH19-737

doi: 10.3205/19ifssh1386, urn:nbn:de:0183-19ifssh13862

Veröffentlicht: 6. Februar 2020

© 2020 Mathot et al.
Dieser Artikel ist ein Open-Access-Artikel und steht unter den Lizenzbedingungen der Creative Commons Attribution 4.0 License (Namensnennung). Lizenz-Angaben siehe http://creativecommons.org/licenses/by/4.0/.


Gliederung

Text

Objectives/Interrogation: We hypothesized that seeding human adipose derived Mesenchymal Stem Cells (MSCs) on the surface of clinically available nerve replacement treatments (Avance Nerve graft and NeuraGen Nerve guide) could provide extra biological support and potentially enhances the outcomes of these nerve substitutes.

Methods: An MTS assay examined the viability of human MSCs at different time intervals when a 2mm segment of Avance Nerve Graft (group I) or NeuraGen Nerve Guide (group II) was added to their environment (n=3 per group per time point). MSCs were seeded by using a non-traumatic dynamic seeding strategy, preserving the inner ultrastructure of the nerve substitutes. 1 million MSCs per nerve substitute were transferred to conical tubes containing either a 10 mm Avance nerve graft or a 10 mm NeuraGen nerve guide. The conical tubes were rotated in a bioreactor for 6, 12 and 24 hours after which cell counts were performed to obtain seeding efficiencies. The distribution of the MSCs was mapped with live/dead and Hoechst stains. Fixed cross-sectional sections of the seeded nerve substitutes were Hoechst stained to observe the migration of cells inside the graft.

Results and Conclusions: The viability of MSCs was not influenced by the presence of both nerve substitutes. For group I, a seeding efficiency of 18.23% was obtained after 6 hours, increasing to 66.46% after 12 hours (p<0.001) after which the efficiency decreased to 59.90% after 24 hours (p=1.00). For group II, the seeding efficiency increased from 52.08% after 6 hours to 94.17% after 12 hours (p=0.009) and decreased to 52.50% after 24 hours (p=0.009). Seeding efficiencies were significantly higher for group 2 after 6 and 12 hours of seeding (p=0.007 and p=0.025) (Figure 1). Live/dead stains, Hoechst stains and SEM on all time points showed a uniform distribution of viable MSCs over the entire surface of both nerve substitutes (Figure 2). Cross-sectional sections revealed that the MSCs were absent on the inside of group I, but were present on the inside of group II.

Viable human MSCs can be seeded on both nerve substitutes without harming the inner ultrastructure; 12 hours is the optimal seeding duration. Human MSCs were seeded on the surface of both nerve substitutes in a uniform matter. MSCs only migrated into the NeuraGen nerve guide during dynamic seeding. Our method showed to have great clinical potential to improve and individualize peripheral nerve repair.